About 12,115 results

Factors of Variable Glycemic Control

Although glycemic control is known to reduce complications associated with diabetes, it is an elusive goal for many patients who have the disease. This study aims to identify factors associated with sustained poor glycemic control, some glycemic variability, and wide glycemic variability among diabetes patients over 3 years.

Diet and Diabetes: Better Communication Needed

The authors of this study set out to examine the lifetime prevalence rates of health care professionals giving low-fat diet advice to patients with diabetes. It was found that while many participants received low-fat dietary advice, almost one-third did not. Researchers concluded that increasing rates of diabetes are outpacing increases in provision of low-fat dietary advice.

Persistent Gaps Exist in Continuity of Medication Use for Adults With Diabetes
Clinical Advisor

Jan 31st, 2023 - HealthDay News — A considerable proportion of adults with diabetes do not maintain continuity of use of glucose, blood pressure, or lipid medications, according to a study published online in JAMA Network Open. Puneet Kaur Chehal, PhD, from the Rollins School of Public Health at Emory University in Atlanta, and colleagues examined trends in longitudinal use of glucose, blood pressure, and lipid...

Real-Time CGMs Better; Spinal Cord Stimulation OK'd for DPN; Best Time to Exercise

Jan 31st, 2023 - The 24-month ALERTT1 trial found that switching to a real-time continuous glucose monitor from an intermittently scanned one significantly improved glycemic control and hypoglycemia worry score for people with type 1 diabetes. (The Lancet Diabetes & Endocrinology) An average of one in five U.S. adults with diabetes didn't keep up with their glucose-lowering medication from 2005 to 2019, a seria...

What Happens When Patients Stop Weight-Loss Medications?

Jan 31st, 2023 - In this video, Ania Jastreboff, MD, PhD, a professor at Yale School of Medicine and director of weight management and obesity prevention at Yale Stress Center in New Haven, Connecticut, discusses what to expect when stopping obesity medications like semaglutide (Wegovy). The following is a transcript of her remarks: Semaglutide, like other medications that are used for obesity treatment, have t...

Supervised Exercise Keeps Diabetes at Bay a Decade Later

Jan 30th, 2023 - Supervised moderate and vigorous aerobic activity helped stave off type 2 diabetes in at-risk individuals with central obesity and nonalcoholic fatty liver disease, according to 10-year follow-up of a randomized trial from China. Compared with adults who did not exercise, the risk of diabetes was reduced by 49% in the vigorous exercise group (relative risk [RR] 0.51, 95% CI 0.27-0.94, P=0.01) a...

Emergency Department Screening Detects Prediabetes, Type 2 Diabetes
Clinical Advisor

Jan 26th, 2023 - HealthDay News — An emergency department type 2 diabetes screening program can identify patients with undiagnosed prediabetes and diabetes, according to a research letter published online in JAMA Network Open. Kirstie K. Danielson, PhD, from the University of Illinois Chicago, and colleagues developed and piloted an type 2 diabetes screening program. Patients at risk for type 2 diabetes were fl...

ED Screening Program Picks Up Lots of Undiagnosed Diabetes Cases

Jan 26th, 2023 - More than half of at-risk patients screened for diabetes at an urban emergency department (ED) were identified as having an abnormal HbA1c during a pilot program, researchers reported. The program was designed to flag the electronic health records (EHRs) of patients at risk for type 2 diabetes with a "best practice alert." During the 3-month study period, alerts were triggered for about 30% of ...

Older People With Type 2 Diabetes See Growing Cancer Burden

Jan 24th, 2023 - Older people with type 2 diabetes faced a higher burden of cancer mortality in recent years, according to a U.K. study. In a cohort of over 137,000 individuals with type 2 diabetes, all-cause mortality rates dropped among all age groups from 1998-2018, reported Suping Ling, PhD, of the University of Leicester in England, and colleagues. However, this was juxtaposed by an increase in cancer-rela...

Eli Lilly to invest $450 million more to expand capacity as obesity drug decision looms

Jan 24th, 2023 - (Reuters) -Eli Lilly and Co plans to invest an additional $450 million to expand capacity of a plant in North Carolina, the U.S. drugmaker said on Tuesday, as it races to boost production ahead of a decision on its promising obesity treatment. The company has been struggling to meet strong demand for its incretin products, which include its blockbuster diabetes drug Trulicity and recently launc...

Jardiance Under Review for CKD; Frailty in Obesity; DIY Semaglutide?

Jan 24th, 2023 - The FDA is reviewing a potential new indication for empagliflozin (Jardiance) for risk reduction of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD) based on the EMPA-KIDNEY phase III trial, Boehringer Ingelheim and Eli Lilly announced. Why did NYU Langone Health abruptly withdraw from a study testing the bacillus Calmette-Guerin vaccine for adoles...

Diabetes Drug for Cats Now Approved in Humans Too

Jan 23rd, 2023 - The first oral SGLT2 inhibitor approved by the FDA for treating diabetes in cats is now approved for humans with the disease, drugmaker TheracosBio announced. As an adjunct to diet and exercise, the oral treatment is indicated for adults with type 2 diabetes, and is not recommended for those with type 1 diabetes or for patients in diabetic ketoacidosis, according to the company. Of note, the on...

Greater Chance of Diabetes Complications With High-Deductible Plan

Jan 20th, 2023 - Switching to high-deductible health plans (HDHPs) spelled trouble when it came to diabetes complications, a retrospective cohort study found. In a group of over 40,000 patients whose employers forced a switch to an HDHP from a non-HDHP, the health plan pivot initially wasn't linked with an overall increased odds for a hypoglycemia-related emergency department (ED) visit or hospitalization (OR 1...

Total Nitrites Consumption Tied to Higher Type 2 Diabetes Risk
Clinical Advisor

Jan 19th, 2023 - HealthDay New — Total nitrites and additive-originated nitrites are linked to higher diabetes risk, according to a study published in PLOS Medicine. Bernard Srour, PhD, MPH, from Sorbonne Paris Nord University, and colleagues examined the association between nitrites/nitrates and , distinguishing foods and water-originated nitrites/nitrates from those from food additives. The analysis included ...

Sodium Nitrite in Food, Water Tied to Type 2 Diabetes Risk

Jan 17th, 2023 - Greater daily exposure to nitrites in food and water may increase the risk for type 2 diabetes, French researchers reported. Compared with those in the lowest tertile of total nitrite exposure (mean 3.3 mg/day), those exposed to the most nitrites -- a mean 8.6 mg/day -- had a 27% greater risk for type 2 diabetes (HR 1.27, 95% CI 1.04-1.54, P=0.009 for trend), according to Bernard Srour, PhD, Ph...

Rybelsus Now First-Line Option for Type 2 Diabetes Following Label Update
Clinical Advisor

Jan 17th, 2023 - The Food and Administration (FDA) has approved updated labeling for Rybelsus® (semaglutide) 7 mg and 14 mg tablets allowing use as a first-line treatment option for adults with type 2 diabetes. is a glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with mellitus. In 2019, the treatment was . The approval was based o...

Rybelsus Now OK'd in First Line; Menopause Before Transition; Novel T2D Drug Flops

Jan 17th, 2023 - Oral semaglutide (Rybelsus) received an expanded label to include first-line treatment for adults with type 2 diabetes as an adjunct to diet and exercise, Novo Nordisk announced. The Obesity Society and Obesity Action Coalition lent support to the American Academy of Pediatrics' new childhood obesity guidelines in a statement, emphasizing that pediatric obesity is a disease and that early inter...

California Attorney General Sues Drugmakers Over Inflated Insulin Prices
Clinical Advisor

Jan 13th, 2023 - California Attorney General Rob Bonta sued the 6 major companies that dominate the US insulin market, ratcheting up the state’s assault on a profitable industry for artificially jacking up prices and making the indispensable drug less accessible for diabetes patients. The alleges 3 pharmaceutical companies that control the insulin market — Eli Lilly and Co., Sanofi, and Novo Nordisk — are viola...

How Many Times Do You Need to Get Out of Your Chair in an Otherwise Sedentary Day?

Jan 12th, 2023 - Frequency and duration both play a role in the extent that an intervention to reduce sedentary time can improve cardiometabolic measures, a small randomized trial found. Compared with uninterrupted sitting, light walking breaks of 5 minutes every half an hour significantly and acutely reduced glucose levels, while taking breaks less frequently -- once an hour -- did not confer such an effect, a...

Type 2 Diabetes Patients Can Also Benefit From Fully Closed-Loop System

Jan 11th, 2023 - Even patients with type 2 diabetes can benefit from using a fully closed-loop insulin delivery system, also known as an artificial pancreas, according to an open-label crossover trial. In the randomized trial of 28 adults, patients spent a greater average proportion of time in target glucose range -- 70 to 180 mg/dL (3.9 to 10.0 mmol/L) -- while on the closed-loop system compared with a control...